Navigation Links
Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
Date:12/20/2007

NEW YORK, Dec. 20 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI), today announced it has initiated a sleep maintenance insomnia (SMI) Phase 2 clinical study using its drug candidate ITI-722. ITI-722 acts predominantly as a selective 5-HT2A receptor antagonist and represents an important new approach to the treatment of SMI. Because of its novel separation of 5-HT2A and dopamine receptor modulatory activities, ITI believes, ITI-722 can be used not only to treat SMI but it may be highly appropriate for the treatment of sleep disorders that accompany neurodegenerative disorders, including Parkinson's disease and other psychiatric disorders.

"The progression of ITI-722 into Phase 2 for SMI represents the advancement of this important new class of therapeutics," stated Sharon Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies. "This drug candidate has therapeutic potential to treat SMI in the general population, and in other patient populations who have been underserved, particularly peri- and post-menopausal women, and in other disorders where insomnia is a problem, including osteoarthritis, depression, Parkinson's disease and other neurologic and psychiatric disorders."

The Phase 2 program is a multi-center, randomized, double-blind placebo- controlled study in patients with SMI. The primary endpoint is an assessment of objective slow wave sleep using polysomnography (PSG). Secondary endpoints include other objective and subjective measures of SMI and sleep efficiency. Additionally, the study will make an assessment regarding next-day cognitive performance.

ITI-722 is a low-dose formulation of ITI-007, ITI's first-in-class 5-HT2A antagonist/ dopamine receptor protein phosphorylation modulator (DPPM), presently in clinical trials for the treatment of schizophrenia.

About Sleep Maintenance Disorders

From nightmares to insomnia to sleep apnea, sleep disorders disrupt the sleep of millions of peopl
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
2. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
3. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
4. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
7. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ober 7 /-,Sosei Group Corpo...ura,Group plc ("Vectura"; LSE: VEC), announce resu...y, safety and tolerability of NVA237 presented at ...ciety (ERS) in Berlin,Germany. The new data show ...led long-acting muscarinic antagonist (LAMA), prov...
(Date:10/6/2008)... the understanding of and possible treatm...LLERICA, Mass., Oct. 6 /- Seahorse Bi...ever analytical instrument for the,kinetic measure...lasmic,glycolysis in cells in a 96 well microplate...ar bioenergetics have been relatively unchanged si...
(Date:10/6/2008)...t The American College of Nutrition .../- New research on the benefits of,pr...The American College of,Nutrition (ACN) Annual Mee...obiotics in Health and Disease." Scientific expert...n discussed the potential uses for,probiotics in c...
(Date:10/6/2008)... Oct. 6 /- Complete,Genomics Inc., a ...encing,company, and the Institute for Systems Biol...duct populationwide human genome studies., In pha...its proprietary,DNA sequencing technology to seque...n, once proof-of-concept has been demonstrated, IS...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 2'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 4Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2Climate change could impact vital functions of microbes 20921 1Climate change could impact vital functions of microbes 20921 2Climate change could impact vital functions of microbes 20921 3Natural Solutions Names 45 Must Have Foods for Healthy Weight Loss 20916 1Natural Solutions Names 45 Must Have Foods for Healthy Weight Loss 20916 2Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference 5756 1Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference 5756 2EntreMed Presents MKC 1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2305 1EntreMed Presents MKC 1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2305 2EntreMed Presents MKC 1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2305 3EntreMed Presents MKC 1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2305 4
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...t even older patients benefit from timely treatmen...ttack), a researcher //has warned in the latest is...ating people over 80 in a timely manner. In other ...geism is rampant in health services. Professor Jo...
...s are linked to allergic reaction in a manner with... are released. However, researchers at Karolinska/...e diseases like psoriasis and cancer. Mast cells...p with allergic reactions, as they behave similar ...
...tenance of strong bones, strong and healthy teeth,...al, calcium.// It is vital to take plenty of cal...ect bones later in life and to prevent osteoporosi...es place till the age of 30-35. Bone mass can be b...
...searchers from the University of Kentucky being cl...preventing blood clots during procedures so// as t...ccording to Dr. Steven Steinhubl, the co-chairman ... to appear in the latest issue of the New England ...
Other Medicine News:Health News:Cancer and psoriasis triggered by mast cells 2Health News:Enoxaparin To Become The Standard Treatment During Procedures For Blocked Arteries 2
14 cm - 5 1/2, 6.0 mm , for drill handles and hand drills.
Hudson Cranial Drill, complete, consisting of: brace; with extension piece and 4 burs
23 cm - 9, adult size, for skull thickness up to 12 mm.
Length-9 (229 mm) Tapered retractor blades.
Medicine Products: